Unexpected contribution of cytochrome P450 enzymes CYP11B2 and CYP21, as well as CYP3A4 in xenobiotic androgen elimination - Insights from metandienone metabolism

Toxicology Letters

Volumn 213, Issue 3, 2012, Pages 381-391

  Parr, Maria Kristina ^a,b   Zöllner, Andy ^c,d   Fußhöller, Gregor ^b   Opfermann, Georg ^b   Schlörer, Nils ^e   Zorio, Mirela ^f   Bureik, Matthias ^c   Schänzer, Wilhelm ^b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^c PomBioTech GmbH   (Germany)

^d Dunn Labortechnik GmbH   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f National Anti Doping Agency   (Romania)

Author keywords

Cytochrome P450; Doping control; GC MS MS; Metabolic pathways; Metandienone; NMR

Indexed keywords

11BETA HYDROXYMETANDIENONE; 18 HYDROXYMETANDIENONE; ALDOSTERONE SYNTHASE; CYTOCHROME P450 3A4; METANDIENONE; STEROID 21 MONOOXYGENASE; UNCLASSIFIED DRUG;

ARTICLE; DOPING; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ANALYSIS; GAS CHROMATOGRAPHY; HORMONE METABOLISM; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; URINALYSIS; WAGNER MEERWEIN REARRANGEMENT;

ADMINISTRATION, ORAL; ALDOSTERONE SYNTHASE; ANABOLIC AGENTS; BIOTRANSFORMATION; CYTOCHROME P-450 CYP3A; DOPING IN SPORTS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYDROXYLATION; MALE; METHANDROSTENOLONE; MIDDLE AGED; PERFORMANCE-ENHANCING SUBSTANCES; RECOMBINANT PROTEINS; STEROID 21-HYDROXYLASE; SUBSTANCE ABUSE DETECTION; SUBSTRATE SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 84865436734     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2012.07.020     Document Type: Article

References (41)

1. Basaria S. Androgen abuse in athletes: detection and consequences. Journal of Clinical Endocrinology and Metabolism 2010, 95:1533-1543.
2. Brodie H.J., Kripalan, Kj, Possanza G. Studies on mechanism of estrogen biosynthesis. 6. Stereochemistry of hydrogen elimination at C-2 during aromatization. The Journal of the American Chemical Society 1969, 91:1241.
3. Bureik M., Lisurek M., Bernhardt R. The human steroid hydroxylases CYP1B1 and CYP11B2. Biological Chemistry 2002, 383:1537-1551.
4. Bureik M., Schiffler B., Hiraoka Y., Vogel F., Bernhardt R. Functional expression of human mitochondrial CYP11B2 in fission yeast and identification of a new internal electron transfer protein, etp1. Biochemistry 2002, 41:2311-2321.
5. Cole P.A., Robinson C.H. Mechanism and inhibition of cytochrome P-450 aromatase. Journal of Medicinal Chemistry 1990, 33:2933-2942.
6. Donike M. N-methyl-N-trimethylsilyl-trifluoroacetamide a new silylating agent from series of silylated amides. Journal of Chromatography 1969, 42:103-104.
7. Dragan C.A., Peters F.T., Bour P., Schwaninger A.E., Schaan S.M., Neunzig I., Widjaja M., Zapp J., Kraemer T., Maurer H.H., Bureik M. Convenient gram-scale metabolite synthesis by engineered fission yeast strains expressing functional human P450 systems. Applied Biochemistry and Biotechnology 2011, 163:965-980.
8. Geyer H., Schänzer W., Mareck-Engelke U., Nolteernsting E., Opfermann G. Screening procedure for anabolic steroids-control of hydrolysis with deuterated androsterone glucuronide and studies with direct hydrolysis. Recent Advances in Doping Analysis 1998, vol. 5:99-102. Sport und Buch Strauss, Köln.
9. Gould D.H., Herzog H.L., Hershberg E.B. New Progestational Agents 1957, Schering Corp., United States. U.S.P. Office (Ed.).
10. Guengerich F.P. Human cytochrome P450 enzymes. Cytochrome P450-Structure, Mechanism, and Biochemistry 2005, 377-530. Kluwer Academic/Plenum Publishers, New York. P.R. Ortiz de Montellano (Ed.).
11. Guengerich F.P., Tang Z., Cheng Q., Salamanca-Pinzon S.G. Approaches to deorphanization of human and microbial cytochrome P450 enzymes. Biochimica et Biophysica Acta 2011, 1814:139-145.
12. Hannemann F., Bichet A., Ewen K.M., Bernhardt R. Cytochrome P450 systems - biological variations of electron transport chains. Biochimica et Biophysica Acta 2006, 1770:330-344.
13. Kawamoto T., Mitsuuchi Y., Ohnishi T., Ichikawa Y., Yokoyama Y., Sumimoto H., Toda K., Miyahara K., Kuribayashi I., Nakao K., Hosoda K., Yamamoto Y., Imura H., Shizuta Y. Cloning and expression of a cDNA for human cytochrome P450ALDO as related to primary aldosteronism. Biochemical and Biophysical Research Communications 1990, 173:309-316.
14. Kawamoto T., Mitsuuchi Y., Toda K., Miyahara K., Yokoyama Y., Nakao K., Hosoda K., Yamamoto Y., Imura H., Shizuta Y. Cloning of cDNA and genomic DNA for human cytochrome P-45011 beta. FEBS Letters 1990, 269:345-349.
15. Korzekwa K.R., Trager W.F., Smith S.J., Osawa Y., Gillette J.R. Theoretical studies on the mechanism of conversion of androgens to estrogens by aromatase. Biochemistry 1991, 30:6155-6162.
16. Miller W.L., Auchus R.J. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocrine Reviews 2011, 32:81-151.
17. Mornet E., Dupont J., Vitek A., White P.C. Characterization of 2 genes encoding human steroid 11-beta-hydroxylase (P-45011-BETA). Journal of Biological Chemistry 1989, 264:20961-20967.
18. Nelson D.R. Progress in tracing the evolutionary paths of cytochrome P450. Biochimica et Biophysica Acta 2011, 1814:14-18.
19. Nitta I., Fujimori S., Ueno H. The syntheses of the corticoid side-chain. 1. An improved method for the preparation of 17-alpha-hydroxyprogesterone from androst-4-ene-3,17-dione. Bulletin of the Chemical Society of the Japan 1985, 58:978-980.
20. Parr M.K., Opfermann G., Piper T., Schlörer N., Fußhöller G., Thomas A., Thevis M., Schänzer W. Characterisation of steroid metabolites recently detected in doping control analyses. Recent Advances in Doping Analysis 2007, vol. 15:143-152. Sport und Buch Strauß, Köln.
21. Parr M.K., Zoellner A., Fußhöller G., Opfermann G., Hobler A., Bernhardt R., Bureik M., Schänzer W. New players in the nightwatch research. Recent Advances in Dope Analysis 2011, vol. 19:60-62. Sport und Buch Strauß, Cologne.
22. Rendic S., Nolteernsting E., Schänzer W. Metabolism of anabolic steroids by recombinant human cytochrome P450 enzymes: gas chromatographic-mass spectrometric determination of metabolites. Journal of Chromatography B 1999, 735:73-83.
23. Sagara Y., Wada A., Takata Y., Waterman M.R., Sekimizu K., Horiuchi T. Direct expression of adrenodoxin reductase in Escherichia coli and the functional characterization. Biological and Pharmaceutical Bulletin 1993, 16:627-630.
24. Schänzer W., Opfermann G., Donike M. Metabolism of stanozolol-identification and synthesis of urinary metabolites. Journal of Steroid Biochemistry and Molecular Biology 1990, 36:153-174.
25. Schänzer W., Geyer H., Donike M. Metabolism of metandienone in man-identification and synthesis of conjugated excreted urinary metabolites, determination of excretion rates and gas-chromatographic mass-spectrometric identification of bis-hydroxylated metabolites. Journal of Steroid Biochemistry and Molecular Biology 1991, 38:441-464.
26. Schänzer W., Opfermann G., Donike M. 17-Epimerization of 17-alpha-methyl anabolic-steroids in humans-metabolism and synthesis of 17-alpha-hydroxy-17-beta-methyl steroids. Steroids 1992, 57:537-550.
27. Schänzer W., Opfermann G., Donike M. 17-Epimerization of 17α-methyl anabolic steroids in humans: metabolism and synthesis of 17α-hydroxy-17β-methyl steroids. Steroids 1992, 57:537-550.
28. Schänzer W., Donike M. Metabolism of anabolic-steroids in man-synthesis and use of reference substances for identification of anabolic-steroid metabolites. Analytica Chimica Acta 1993, 275:23-48.
29. Schänzer W., Donike M. Synthesis of deuterated steroids for GC/MS quantification of endogenous steorids. Recent Advances in Doping Analysis 1995, vol. 2:93-112. Sport und Buch Strauß, Köln.
30. Schänzer W., Horning S., Donike M. Metabolism of anabolic-steroids in humans-synthesis of 6-beta-hydroxy metabolites of 4-chloro-1,2-dehydro-17-alpha-methyltestosterone, fluoxymesterone, and metandienone. Steroids 1995, 60:353-366.
31. Schänzer W., Delahaut P., Geyer H., Machnik M., Horning S. Long-term detection and identification of metandienone and stanozolol abuse in athletes by gas chromatography high-resolution mass spectrometry. Journal of Chromatography B 1996, 687:93-108.
32. Schänzer W., Geyer H., Horning S. 17,17-Dimethyl-18-nor-5α-androst-1,13-dien-3α-ol (18-normetenol) in longterm detection and confirmation of positive metandienone cases. Recent Advances in Doping Analysis 1999, vol. 6:37-52. Sport und Buch Strauß, Köln.
33. Schänzer W., Geyer H., Fußhöller G., Halatcheva N., Kohler M., Parr M.K., Guddat S., Thomas A., Thevis M. Mass spectrometric identification and characterization of a new long-term metabolite of metandienone in human urine. Rapid Communications in Mass Spectrometry 2006, 20:2252-2258.
34. Uhlmann H., Beckert V., Schwarz D., Bernhardt R. Expression of bovine adrenodoxin in E. coli and site-directed mutagenesis of/2Fe-2S/cluster ligands. Biochemical and Biophysical Research Communications 1992, 188:1131-1138.
35. Wood V., Gwilliam R., Rajandream M.A., Lyne M., Lyne R., Stewart A., Sgouros J., Peat N., Hayles J., Baker S., Basham D., Bowman S., Brooks K., Brown D., Brown S., Chillingworth T., Churcher C., Collins M., Connor R., Cronin A., Davis P., Feltwell T., Fraser A., Gentles S., Goble A., Hamlin N., Harris D., Hidalgo J., Hodgson G., Holroyd S., Hornsby T., Howarth S., Huckle E.J., Hunt S., Jagels K., James K., Jones L., Jones M., Leather S., McDonald S., McLean J., Mooney P., Moule S., Mungall K., Murphy L., Niblett D., Odell C., Oliver K., O'Neil S., Pearson D., Quail M.A., Rabbinowitsch E., Rutherford K., Rutter S., Saunders D., Seeger K., Sharp S., Skelton J., Simmonds M., Squares R., Squares S., Stevens K., Taylor K., Taylor R.G., Tivey A., Walsh S., Warren T., Whitehead S., Woodward J., Volckaert G., Aert R., Robben J., Grymonprez B., Weltjens I., Vanstreels E., Rieger M., Schafer M., Muller-Auer S., Gabel C., Fuchs M., Fritzc C., Holzer E., Moestl D., Hilbert H., Borzym K., Langer I., Beck A., Lehrach H., Reinhardt R., Pohl T.M., Eger P., Zimmermann W., Wedler H., Wambutt R., Purnelle B., Goffeau A., Cadieu E., Dreano S., Gloux S., Lelaure V., Mottier S., Galibert F., Aves S.J., Xiang Z., Hunt C., Moore K., Hurst S.M., Lucas M., Rochet M., Gaillardin C., Tallada V.A., Garzon A., Thode G., Daga R.R., Cruzado L., Jimenez J., Sanchez M., del Rey F., Benito J., Dominguez A., Revuelta J.L., Moreno S., Armstrong J., Forsburg S.L., Cerrutti L., Lowe T., McCombie W.R., Paulsen I., Potashkin J., Shpakovski G.V., Ussery D., Barrell B.G., Nurse P. The genome sequence of Schizosaccharomyces pombe. Nature 2002, 415:871-880.
36. World Anti-Doping Agency, 2010. Adverse analytical findings reported by accredited laboratories. Online at , 27.04.2010. http://www.wada-ama.org/en/Science-Medicine/Anti-Doping-Laboratories/Laboratory-Statistics/.
37. World Anti-Doping Agency, 2010. The 2011 Prohibited List. Online at , 21.03.2011. http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/To_be_effective/WADA_Prohibited_List_2011_EN.pdf.
38. Wu D.A., Hu M.C., Chung B.C. Expression and functional study of wild-type and mutant human cytochrome P450c21 in Saccharomyces cerevisiae. DNA and Cell Biology 1991, 10:201-209.
39. Zöllner A., Kagawa N., Waterman M.R., Nonaka Y., Takio K., Shiro Y., Hannemann F., Bernhardt R. Purification and functional characterization of human 11 beta hydroxylase expressed in Escherichia coli. FEBS Journal 2008, 275:799-810.
40. Zöllner A., Parr M.K., Dragan C.A., Peters F., Maurer H., Schanzer W., Bureik M. CYP21 catalyzed production of 18-nor-17 beta-hydroxymethyl, 17 alpha-methylandrosta-1,4,13-trien-3-one: a new player in the fight against doping. Drug Metabolism Reviews 2009, 41:80.
41. Zöllner A., Parr M.K., Dragan C.-A., Dras S., Schlörer N., Peters F.T., Maurer H.H., Schänzer W., Bureik M. CYP21-catalyzed production of the long-term urinary metandienone metabolite 17beta-hydroxymethyl-17 alpha-methyl-18-norandrosta-1,4,13-trien-3-one: a contribution to the fight against doping. Biological Chemistry 2010, 391:119-127.